ADMA BiologicsADMA
About: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Employees: 624
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,340% more call options, than puts
Call options by funds: $33.2M | Put options by funds: $2.3M
141% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 39
100% more capital invested
Capital invested by funds: $2.08B [Q2] → $4.15B (+$2.08B) [Q3]
22% more funds holding
Funds holding: 250 [Q2] → 304 (+54) [Q3]
17% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 7 (+1) [Q3]
9.32% more ownership
Funds ownership: 80.04% [Q2] → 89.36% (+9.32%) [Q3]
5% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 95
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 119 / 312 met price target | 62%upside $26 | Buy Maintained | 8 Nov 2024 |
Raymond James Elliot Wilbur 50% 1-year accuracy 2 / 4 met price target | 56%upside $25 | Strong Buy Maintained | 8 Nov 2024 |
Financial journalist opinion
Based on 6 articles about ADMA published over the past 30 days
